




Belgian Cancer Registry

## CANCER FACT SHEET 2022

### COLORECTAL CANCER

ICD-10 C18-C20



## CONCEPTS AND ABBREVIATIONS

**Absolute numbers (N):** The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

**Average Annual Percentage Change (AAPC):** The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ( $=200 \times 1.05$ ) and 255/100,000 over 5 years ( $=200 \times (1.05)^5$ ).

**Crude Rate (CR):** The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

**ESR2013:** Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

**Net survival:** Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

**Stage:** Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. For colorectal cancer, stage IV means the cancer has spread to other organs. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8<sup>th</sup> edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

- **Clinical stage:** Stage based on clinical examinations (e.g.: medical imaging, biopsies) to estimate the extent of the tumour. Clinical stage is established before the start of any treatment.
- **Pathological stage:** Stage based on pathological examinations of the tumour after surgery. **Pathological stage without neo-adjuvant therapy** is the pathological stage in the population that did not receive neo-adjuvant therapy prior to surgery. **Pathological stage after neo-adjuvant therapy** is the pathological stage in the population that did receive neo-adjuvant therapy prior to surgery. Pathological stage regardless of neo-adjuvant therapy is reported as (y)pStage.
- **Neo-adjuvant therapy (NAT):** Treatment (e.g.: chemotherapy/radiotherapy) given prior to surgery, with the goal to shrink the tumour before operating.

**95% CI:** 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.



1. CANCER INCIDENCE .....	5
1.1. Colorectal cancer incidence: by region .....	5
1.1.1. Colorectal cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022.....	5
1.2. Colorectal cancer incidence: by tumour stage .....	7
1.2.1. Colorectal cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022 .....	7
1.2.2. Colorectal cancer incidence by pathological stage ((y)pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	7
1.2.3. Colorectal cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	8
1.2.4. Colorectal cancer incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	9
1.2.5. Rectal cancer incidence by stage variables, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	10
2. CANCER INCIDENCE TRENDS .....	11
2.1. Colorectal cancer incidence trends: by region.....	11
2.1.1. Colorectal cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	11
2.1.2. Colorectal cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	13
2.2. Colorectal cancer incidence trends: by tumour stage .....	14
2.2.1. Colorectal cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards...	14
2.3. Colorectal cancer incidence trends: by age group.....	16
2.3.1. Colorectal cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	16
2.3.2. Colorectal cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	17
3. CANCER PREVALENCE .....	18
3.1. Colorectal cancer prevalence: by region.....	18
3.1.1. Colorectal cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022.....	18
4. CANCER SURVIVAL.....	19
4.1. Colorectal cancer survival: by region .....	19
4.1.1. Colorectal cancer survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022.....	19
4.2. Colorectal cancer survival: by sub-location and tumour stage .....	21
4.2.1. Colorectal cancer survival by sub-location, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022 .....	21
4.2.2. Colorectal cancer survival by sub-location, pathological stage ((y)pStage) and sex: number at risk and net survival probabilities, 2013-2022.....	23

4.2.3. Colorectal cancer survival by sub-location, stage and sex: number at risk and net survival probabilities, 2013-2022.....	25
5. CANCER SURVIVAL TRENDS.....	27
5.1. Colorectal cancer survival trends: by tumour stage.....	27
5.1.1. Colorectal cancer survival trends by stage and sex: number at risk and net survival probabilities, 2008-2022 .....	27
5.2. Colorectal cancer survival trends: by sub-location and tumour stage.....	29
5.2.1. Colorectal cancer survival trends by sub-location, stage and sex: number at risk and net survival probabilities, 2008-2022 .....	29
6. CANCER MORTALITY .....	31
6.1. Colorectal cancer mortality: by region.....	31
6.1.1. Colorectal cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021 .....	31
7. CANCER MORTALITY TRENDS.....	33
7.1. Colorectal cancer mortality trends: by region .....	33
7.1.1. Colorectal cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021 .....	33
7.1.2. Colorectal cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021 .....	35

# 1. CANCER INCIDENCE



## 1.1. Colorectal cancer incidence: by region

1.1.1. Colorectal cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Males																						
<b>Belgium</b>	0	2	4	5	12	12	17	36	60	112	214	323	502	615	675	599	529	398	134	19	4,268	80.4
	[0.0]	[0.6]	[1.1]	[1.5]	[3.5]	[3.3]	[4.4]	[9.7]	[15.8]	[29.9]	[54.0]	[79.9]	[136.0]	[196.8]	[255.7]	[314.9]	[417.9]	[507.3]	[446.3]	[324.7]	[74.8]	(77.9; 82.8)
Brussels	0	0	1	0	0	1	3	6	8	11	17	28	41	44	48	41	38	24	10	3	324	84.6
	[0.0]	[0.0]	[2.6]	[0.0]	[0.0]	[2.0]	[5.8]	[12.9]	[17.3]	[25.3]	[42.1]	[80.7]	[146.6]	[207.8]	[290.6]	[336.8]	[470.6]	[471.8]	[461.3]	[562.9]	[54.0]	(75.1; 94.1)
Flanders	0	2	1	3	9	5	9	22	33	64	123	173	286	329	368	346	337	278	94	12	2,494	75.2
	[0.0]	[1.1]	[0.5]	[1.6]	[4.8]	[2.5]	[4.3]	[10.5]	[15.1]	[30.3]	[53.2]	[70.8]	[127.2]	[171.3]	[227.6]	[280.3]	[403.3]	[529.9]	[471.7]	[317.5]	[75.2]	(72.2; 78.2)
Wallonia	0	0	2	2	3	6	5	8	19	37	74	122	175	242	259	212	154	96	30	4	1,450	89.8
	[0.0]	[0.0]	[1.8]	[1.8]	[2.6]	[5.4]	[4.2]	[6.9]	[16.4]	[30.7]	[59.5]	[97.5]	[150.6]	[243.8]	[301.8]	[388.2]	[440.5]	[459.5]	[378.3]	[260.1]	[80.9]	(85.1; 94.4)
Females																						
<b>Belgium</b>	0	0	5	11	3	12	23	39	64	98	155	224	310	359	466	509	530	410	191	28	3,437	53.2
	[0.0]	[0.0]	[1.5]	[3.5]	[0.9]	[3.3]	[6.0]	[10.5]	[16.9]	[26.7]	[40.1]	[56.2]	[82.3]	[107.9]	[157.8]	[220.3]	[297.4]	[304.4]	[275.2]	[136.5]	[58.5]	(51.4; 55.0)
Brussels	0	0	0	1	1	5	3	8	4	9	13	24	19	26	30	36	43	27	17	1	267	51.4
	[0.0]	[0.0]	[0.0]	[2.9]	[2.5]	[9.2]	[5.7]	[16.9]	[8.9]	[22.4]	[34.9]	[71.1]	[63.9]	[104.4]	[140.7]	[208.8]	[330.1]	[268.4]	[294.5]	[48.5]	[42.9]	(45.1; 57.6)

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Flanders	0	0	5	5	2	4	18	18	42	47	85	123	174	201	257	297	332	247	112	20	1,989	50.7
	[0.0]	[0.0]	[2.7]	[2.9]	[1.1]	[2.0]	[8.5]	[8.6]	[19.4]	[22.7]	[37.7]	[51.6]	[77.5]	[101.6]	[148.0]	[207.7]	[296.4]	[290.2]	[263.0]	[165.6]	[58.8]	(48.5; 53.0)
Wallonia	0	0	0	5	0	3	2	13	18	42	57	77	117	132	179	176	155	136	62	7	1,181	58.2
	[0.0]	[0.0]	[0.0]	[4.7]	[0.0]	[2.8]	[1.7]	[11.2]	[15.5]	[35.0]	[45.8]	[60.7]	[95.6]	[120.0]	[178.5]	[248.3]	[291.5]	[344.3]	[294.8]	[109.8]	[63.1]	(54.9; 61.6)

## 1.2. Colorectal cancer incidence: by tumour stage

1.2.1. Colorectal cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

cStage	Males					Females						
	N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)				
	15-49	50-74	75+	All ages			15-49	50-74	75+	All ages		
I	42 [1.6]	453 [25.9]	314 [72.8]	810 [14.2]	15.3 (14.2; 16.3)			46 [1.8]	287 [16.0]	285 [45.0]	619 [10.5]	9.7 (8.9; 10.4)
II	37 [1.5]	364 [20.9]	347 [80.5]	750 [13.1]	14.3 (13.3; 15.4)			34 [1.4]	268 [15.0]	371 [58.5]	673 [11.5]	10.2 (9.4; 11.0)
III	62 [2.4]	571 [32.7]	334 [77.5]	968 [17.0]	17.9 (16.8; 19.1)			58 [2.3]	359 [20.1]	387 [61.1]	804 [13.7]	12.4 (11.6; 13.3)
IV	50 [2.0]	496 [28.4]	348 [80.7]	894 [15.7]	16.8 (15.7; 17.9)			47 [1.9]	296 [16.5]	276 [43.5]	619 [10.5]	9.7 (8.9; 10.5)
X/NA	63 [2.5]	445 [25.5]	336 [77.9]	846 [14.8]	16.0 (14.9; 17.1)			65 [2.6]	304 [17.0]	349 [55.1]	722 [12.3]	11.2 (10.4; 12.0)

1.2.2. Colorectal cancer incidence by pathological stage ((y)pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

(y)pStage	Males					Females						
	N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)				
	15-49	50-74	75+	All ages			15-49	50-74	75+	All ages		
I	65 [2.6]	624 [35.7]	325 [75.4]	1,016 [17.8]	18.8 (17.6; 20.0)			65 [2.6]	374 [20.9]	334 [52.7]	775 [13.2]	12.3 (11.4; 13.1)
II	57 [2.2]	492 [28.2]	433 [100.4]	985 [17.3]	18.7 (17.5; 19.9)			52 [2.1]	353 [19.7]	462 [72.9]	869 [14.8]	13.3 (12.4; 14.2)
III	63 [2.5]	541 [31.0]	351 [81.4]	956 [16.7]	17.8 (16.7; 19.0)			56 [2.2]	364 [20.3]	391 [61.7]	811 [13.8]	12.5 (11.7; 13.4)
IV	21 [0.8]	171 [9.8]	84 [19.5]	276 [4.8]	5.1 (4.5; 5.7)			32 [1.3]	128 [7.1]	87 [13.7]	247 [4.2]	4.0 (3.5; 4.5)
X/NA	48 [1.9]	501 [28.7]	486 [112.7]	1,035 [18.1]	19.9 (18.7; 21.1)			45 [1.8]	295 [16.5]	394 [62.2]	735 [12.5]	11.1 (10.3; 11.9)

1.2.3. Colorectal cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-49	50-74	75+	All ages		15-49	50-74	75+	All ages	
<b>I</b>	61 [2.4]	593 [34.0]	355 [82.3]	1,011 [17.7]	18.9 (17.7; 20.1)	56 [2.2]	352 [19.7]	345 [54.4]	756 [12.9]	11.8 (11.0; 12.7)
<b>II</b>	59 [2.3]	470 [26.9]	466 [108.1]	998 [17.5]	19.1 (17.9; 20.3)	54 [2.2]	357 [19.9]	495 [78.1]	908 [15.5]	13.8 (12.9; 14.7)
<b>III</b>	69 [2.7]	679 [38.9]	402 [93.2]	1,151 [20.2]	21.4 (20.1; 22.6)	71 [2.8]	439 [24.5]	450 [71.0]	960 [16.3]	14.9 (13.9; 15.8)
<b>IV</b>	58 [2.3]	532 [30.5]	370 [85.8]	960 [16.8]	18.0 (16.9; 19.2)	56 [2.2]	317 [17.7]	300 [47.3]	673 [11.5]	10.6 (9.8; 11.4)
<b>X/NA</b>	7 [0.3]	55 [3.2]	86 [19.9]	148 [2.6]	3.0 (2.5; 3.4)	13 [0.5]	49 [2.7]	78 [12.3]	140 [2.4]	2.1 (1.8; 2.5)



1.2.4. Colorectal cancer incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Sub-locations	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-49	50-74	75+	All ages		15-49	50-74	75+	All ages	
Colon	I	40 [1.6]	369 [21.1]	253 [58.7]	664 [11.6]	12.5 (11.5; 13.4)	31 [1.2]	261 [14.6]	276 [43.5]	570 [9.7]	8.9 (8.1; 9.6)
	II	50 [2.0]	361 [20.7]	390 [90.5]	804 [14.1]	15.4 (14.4; 16.5)	47 [1.9]	307 [17.1]	427 [67.4]	783 [13.3]	11.9 (11.1; 12.7)
	III	41 [1.6]	366 [21.0]	269 [62.4]	677 [11.9]	12.7 (11.7; 13.7)	38 [1.5]	264 [14.7]	327 [51.6]	629 [10.7]	9.6 (8.8; 10.4)
	IV	38 [1.5]	378 [21.7]	277 [64.2]	693 [12.1]	13.1 (12.1; 14.0)	45 [1.8]	251 [14.0]	246 [38.8]	542 [9.2]	8.5 (7.8; 9.2)
	X/NA	4 [0.2]	28 [1.6]	54 [12.5]	86 [1.5]	1.8 (1.4; 2.2)	6 [0.2]	28 [1.6]	60 [9.5]	94 [1.6]	1.4 (1.1; 1.7)
Rectum	I	21 [0.8]	224 [12.8]	102 [23.7]	347 [6.1]	6.4 (5.7; 7.1)	25 [1.0]	91 [5.1]	69 [10.9]	186 [3.2]	3.0 (2.5; 3.4)
	II	9 [0.4]	109 [6.2]	76 [17.6]	194 [3.4]	3.6 (3.1; 4.2)	7 [0.3]	50 [2.8]	68 [10.7]	125 [2.1]	1.9 (1.6; 2.2)
	III	28 [1.1]	313 [17.9]	133 [30.8]	474 [8.3]	8.7 (7.9; 9.5)	33 [1.3]	175 [9.8]	123 [19.4]	331 [5.6]	5.3 (4.7; 5.9)
	IV	20 [0.8]	154 [8.8]	93 [21.6]	267 [4.7]	5.0 (4.4; 5.6)	11 [0.4]	66 [3.7]	54 [8.5]	131 [2.2]	2.1 (1.7; 2.5)
	X/NA	3 [0.1]	27 [1.5]	32 [7.4]	62 [1.1]	1.2 (0.9; 1.5)	7 [0.3]	21 [1.2]	18 [2.8]	46 [0.8]	0.7 (0.5; 0.9)

1.2.5. Rectal cancer incidence by stage variables, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Stage variables	Stage	Males					Females				
		N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
		15-49	50-74	75+	All ages			15-49	50-74	75+	All ages
Clinical stage	I	16 [0.6]	178 [10.2]	78 [18.1]	272 [4.8]	5.0 (4.4; 5.6)	21 [0.8]	84 [4.7]	63 [9.9]	169 [2.9]	2.7 (2.3; 3.1)
	II	6 [0.2]	104 [6.0]	75 [17.4]	185 [3.2]	3.5 (3.0; 4.0)	6 [0.2]	54 [3.0]	68 [10.7]	128 [2.2]	1.9 (1.6; 2.3)
	III	32 [1.3]	302 [17.3]	134 [31.1]	468 [8.2]	8.6 (7.8; 9.4)	35 [1.4]	160 [8.9]	117 [18.5]	312 [5.3]	5.0 (4.4; 5.5)
	IV	20 [0.8]	152 [8.7]	91 [21.1]	263 [4.6]	4.9 (4.3; 5.5)	10 [0.4]	64 [3.6]	53 [8.4]	127 [2.2]	2.0 (1.7; 2.4)
	X/NA	7 [0.3]	91 [5.2]	58 [13.5]	156 [2.7]	2.9 (2.5; 3.4)	11 [0.4]	41 [2.3]	31 [4.9]	83 [1.4]	1.3 (1.0; 1.6)
Pathological stage without NAT	I	19 [0.7]	195 [11.2]	79 [18.3]	293 [5.1]	5.4 (4.7; 6.0)	22 [0.9]	84 [4.7]	51 [8.0]	157 [2.7]	2.5 (2.1; 2.9)
	II	4 [0.2]	38 [2.2]	29 [6.7]	71 [1.2]	1.3 (1.0; 1.7)	2 [0.1]	19 [1.1]	31 [4.9]	52 [0.9]	0.8 (0.6; 1.0)
	III	4 [0.2]	66 [3.8]	30 [7.0]	100 [1.8]	1.9 (1.5; 2.2)	4 [0.2]	42 [2.3]	31 [4.9]	77 [1.3]	1.2 (0.9; 1.5)
	IV	1 [0.0]	18 [1.0]	6 [1.4]	25 [0.4]	0.5 (0.3; 0.6)	3 [0.1]	9 [0.5]	6 [0.9]	18 [0.3]	0.3 (0.2; 0.4)
	X/NA	30 [1.2]	239 [13.7]	209 [48.5]	478 [8.4]	9.1 (8.3; 9.9)	25 [1.0]	123 [6.9]	149 [23.5]	298 [5.1]	4.5 (4.0; 5.0)
Pathological stage after NAT	I	6 [0.2]	65 [3.7]	22 [5.1]	93 [1.6]	1.7 (1.3; 2.0)	11 [0.4]	29 [1.6]	20 [3.2]	60 [1.0]	1.0 (0.7; 1.3)
	II	2 [0.1]	78 [4.5]	25 [5.8]	105 [1.8]	1.9 (1.5; 2.2)	3 [0.1]	25 [1.4]	16 [2.5]	44 [0.7]	0.7 (0.5; 0.9)
	III	13 [0.5]	63 [3.6]	21 [4.9]	97 [1.7]	1.8 (1.4; 2.1)	7 [0.3]	35 [2.0]	16 [2.5]	58 [1.0]	0.9 (0.7; 1.2)
	IV	1 [0.0]	13 [0.7]	3 [0.7]	17 [0.3]	0.3 (0.2; 0.5)	2 [0.1]	3 [0.2]	1 [0.2]	6 [0.1]	0.1 (0.0; 0.2)
	X/NA	1 [0.0]	52 [3.0]	12 [2.8]	65 [1.1]	1.2 (0.9; 1.4)	4 [0.2]	34 [1.9]	11 [1.7]	49 [0.8]	0.8 (0.6; 1.1)

## 2. CANCER INCIDENCE TRENDS



### 2.1. Colorectal cancer incidence trends: by region

2.1.1. Colorectal cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period		
<b>Belgium</b>	<b>N</b>	4,108	4,155	4,262	4,249	4,519	4,538	4,592	4,802	4,753	4,804	5,608	4,933	4,768	4,598	4,317	4,326	3,983	4,392	4,268			
	<b>CR</b>	80.8	81.3	82.9	82.0	86.5	86.1	86.4	89.4	87.8	88.2	102.4	89.6	86.1	82.6	77.1	76.9	70.4	77.4	74.8			
	<b>ESR2013</b>		106.1	105.0	106.6	103.0	107.7	106.3	104.7	108.6	105.9	104.9	120.3	103.8	99.1	93.0	86.3	84.6	77.1	84.1	80.4	-1.6 (-2.1; -1.1)	2004-2022
																						0.7 (-0.4; 1.7)	2004-2013
																						-4.3 (-6.4; -2.1)	2014-2017
																						-3.4 (-5.5; -1.2)	2018-2022
Brussels	<b>N</b>	299	316	310	337	337	281	357	356	321	312	320	302	337	333	320	302	265	322	324			
	<b>CR</b>	62.2	65.3	63.3	67.8	66.7	54.4	67.8	65.6	58.1	55.5	56.5	52.7	58.1	57.2	54.5	51.0	44.3	53.7	54.0			
	<b>ESR2013</b>	94.5	96.5	95.2	102.8	101.8	84.1	103.5	103.7	93.3	88.2	90.0	84.4	91.9	91.6	86.0	81.1	70.2	83.1	84.6			
																						-1.2 (-1.9; -0.6)	2004-2022
Flanders	<b>N</b>	2,603	2,642	2,750	2,698	2,933	2,983	2,905	3,083	3,060	3,063	3,928	3,288	2,971	2,774	2,570	2,558	2,459	2,598	2,494			
	<b>CR</b>	87.7	88.7	91.7	89.4	96.5	97.4	94.2	99.0	97.6	97.2	124.1	103.3	92.8	86.1	79.3	78.5	75.0	78.9	75.2			
	<b>ESR2013</b>	110.8	110.2	112.6	106.8	113.9	113.6	107.8	113.6	110.1	107.9	136.1	111.3	99.0	90.3	82.5	80.2	76.3	79.8	75.2			
																						-2.1 (-2.9; -1.4)	2004-2022
																						1.0 (-0.6; 2.5)	2004-2013
																						-6.1 (-9.2; -3.0)	2014-2017
																						-4.3 (-7.4; -1.2)	2018-2022

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
Wallonia <b>N</b>	1,206	1,197	1,202	1,214	1,249	1,274	1,330	1,363	1,372	1,429	1,360	1,343	1,460	1,491	1,427	1,466	1,259	1,472	1,450			
<b>CR</b>	73.5	72.6	72.6	72.8	74.4	75.5	78.2	79.5	79.5	82.4	78.1	76.8	83.1	84.5	80.6	82.6	70.7	82.5	80.9			
<b>ESR2013</b>	100.0	97.2	97.7	95.5	96.8	96.8	99.0	99.8	100.3	103.0	95.3	93.4	100.8	98.8	93.7	94.7	80.6	92.7	89.8	-0.5 (-0.8; -0.1)	2004-2022	
																				0.5 (-0.5; 1.4)	2004-2012	
																					-1.2 (-1.9; -0.5)	2013-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Colorectal cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period			
Belgium	<b>N</b>	3,505	3,466	3,582	3,645	3,717	3,733	3,743	3,760	3,895	3,894	4,132	3,852	3,771	3,650	3,588	3,712	3,343	3,480	3,437				
	<b>CR</b>	66.0	65.0	66.7	67.5	68.3	68.1	67.7	67.4	69.3	68.9	72.8	67.5	65.8	63.4	62.1	64.0	57.3	59.5	58.5				
	<b>ESR2013</b>		66.2	65.0	66.1	66.0	66.8	65.9	65.4	65.0	66.5	66.0	70.5	63.8	62.2	59.3	57.1	58.8	52.5	54.5	53.2	-1.2 (-1.5; -0.9)	2004-2022	
																						0.3 (-0.3; 1.0)	2004-2013	
																						-2.8 (-4.1; -1.5)	2014-2017	
																							-2.6 (-3.9; -1.3)	2018-2022
Brussels	<b>N</b>	327	326	351	294	304	277	319	342	300	298	300	305	306	293	283	318	272	265	267				
	<b>CR</b>	62.9	62.3	66.3	55.0	56.1	50.2	56.7	59.3	51.2	50.3	50.3	50.6	50.3	48.1	46.2	51.6	43.8	42.7	42.9				
	<b>ESR2013</b>	65.1	64.3	70.9	58.6	60.3	54.7	62.3	67.6	58.2	58.6	59.2	60.4	61.1	57.2	54.8	61.7	52.6	51.2	51.4			-1.1 (-1.7; -0.5)	2004-2022
Flanders	<b>N</b>	2,050	2,005	2,142	2,216	2,298	2,335	2,344	2,227	2,398	2,413	2,698	2,377	2,301	2,190	2,135	2,196	2,005	2,083	1,989				
	<b>CR</b>	67.2	65.5	69.5	71.5	73.6	74.3	74.0	69.7	74.6	74.7	83.1	72.9	70.2	66.5	64.5	66.0	59.9	62.0	58.8				
	<b>ESR2013</b>		67.0	64.9	68.1	68.8	70.7	70.2	69.7	65.4	69.1	68.7	77.7	66.1	63.3	59.4	55.9	57.8	52.0	53.6	50.7			-1.7 (-2.0; -1.3)
																							0.5 (-0.2; 1.2)	2004-2014
																								-4.3 (-5.2; -3.4)
Wallonia	<b>N</b>	1,128	1,135	1,089	1,135	1,115	1,121	1,080	1,191	1,197	1,183	1,134	1,170	1,164	1,167	1,170	1,198	1,066	1,132	1,181				
	<b>CR</b>	64.8	64.9	62.0	64.2	62.7	62.7	60.1	65.8	65.7	64.7	61.8	63.6	63.1	63.1	63.1	64.5	57.2	60.7	63.1				
	<b>ESR2013</b>	65.3	65.2	60.9	63.1	61.2	61.1	58.4	63.6	63.7	62.8	59.7	60.8	60.3	59.8	59.7	60.3	53.3	57.0	58.2			-0.6 (-0.9; -0.3)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

## 2.2. Colorectal cancer incidence trends: by tumour stage

2.2.1. Colorectal cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards

Stage	Males							Females							
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
<b>I</b>	<b>N</b>	1,082	1,077	921	1,044	1,011			811	827	744	765	756		
	<b>CR</b>	19.3	19.1	16.3	18.4	17.7			14.0	14.3	12.8	13.1	12.9		
	<b>ESR2013</b>	21.3	20.9	17.6	19.8	18.9	1.1 (-0.1; 2.3)	2004-2022	13.2	13.4	11.9	12.1	11.8	1.6 (0.9; 2.3)	2004-2022
							4.5 (2.8; 6.2)	2004-2017						4.4 (3.4; 5.4)	2004-2017
						-7.2 (-11.5; -2.6)	2018-2022						-5.4 (-8.0; -2.6)	2018-2022	
<b>II</b>	<b>N</b>	1,032	1,030	947	1,055	998			900	972	891	918	908		
	<b>CR</b>	18.4	18.3	16.7	18.6	17.5			15.6	16.7	15.3	15.7	15.5		
	<b>ESR2013</b>	20.8	20.3	18.6	20.4	19.1	-2.5 (-2.8; -2.2)	2004-2022	14.0	15.1	13.8	14.1	13.8	-1.8 (-2.2; -1.5)	2004-2022
							-0.5 (-1.3; 0.2)	2004-2013						-0.5 (-1.3; 0.2)	2004-2013
						-4.4 (-5.1; -3.7)	2014-2022						-3.1 (-3.9; -2.4)	2014-2022	
<b>III</b>	<b>N</b>	1,215	1,196	1,117	1,221	1,151			1,004	995	918	985	960		
	<b>CR</b>	21.7	21.3	19.7	21.5	20.2			17.4	17.1	15.7	16.9	16.3		
	<b>ESR2013</b>	24.3	23.3	21.5	23.2	21.4	-1.3 (-1.8; -0.9)	2004-2022	16.1	15.8	14.5	15.5	14.9	-1.1 (-1.4; -0.8)	2004-2022
							2.1 (1.1; 3.1)	2004-2013						1.1 (0.4; 1.9)	2004-2013
						-4.7 (-5.6; -3.8)	2014-2022						-3.3 (-4.0; -2.5)	2014-2022	
<b>IV</b>	<b>N</b>	828	908	888	969	960			720	806	709	725	673		
	<b>CR</b>	14.8	16.1	15.7	17.1	16.8			12.5	13.9	12.2	12.4	11.5		
	<b>ESR2013</b>	16.5	17.7	17.2	18.6	18.0	0.2 (-0.3; 0.6)	2004-2022	11.6	12.9	11.2	11.5	10.6	0.7 (0.2; 1.2)	2004-2022
							2.0 (0.8; 3.1)	2004-2012						2.8 (1.4; 4.3)	2004-2011
						-2.7 (-4.7; -0.7)	2013-2016						-0.6 (-1.5; 0.2)	2012-2022	

Stage	Males							Females							
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
						-0.3 (-1.9; 1.3)	2017-2022								
<b>X/NA</b>	<b>N</b>	160	115	110	103	148		153	112	81	87	140			
	<b>CR</b>	2.9	2.0	1.9	1.8	2.6		2.6	1.9	1.4	1.5	2.4			
	<b>ESR2013</b>	3.4	2.4	2.2	2.1	3.0	-11.8 (-13.1; -10.4)	2004-2022	2.2	1.6	1.1	1.2	2.1	-11.7 (-13.1; -10.2)	2004-2022
							-9.1 (-12.4; -5.7)	2004-2012							
							-15.3 (-20.8; -9.3)	2013-2016							
							-12.9 (-17.4; -8.1)	2017-2022							

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

## 2.3. Colorectal cancer incidence trends: by age group

2.3.1. Colorectal cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
<b>15-39</b>	<b>N</b>	43	55	61	61	49	72	70	66	65	88	56	65	65	85	69	81	72	102	82		
	<b>CR</b>	2.5	3.2	3.5	3.5	2.8	4.1	4.0	3.8	3.7	5.0	3.2	3.7	3.7	4.8	3.9	4.6	4.0	5.7	4.6		
	<b>ESR2013</b>	2.4	3.2	3.5	3.6	2.9	4.2	4.1	3.9	3.8	5.1	3.3	3.8	3.8	4.9	4.0	4.7	4.2	5.8	4.7	2.7 (1.4; 4.1)	2004-2022
<b>40-49</b>	<b>N</b>	194	160	180	175	200	147	175	169	176	187	189	159	171	164	130	173	160	166	172		
	<b>CR</b>	24.6	20.0	22.3	21.5	24.5	18.0	21.5	20.7	21.6	23.1	23.6	20.1	22.0	21.3	17.0	22.7	21.1	21.9	22.8		
	<b>ESR2013</b>	24.8	20.1	22.5	21.7	24.6	18.0	21.4	20.5	21.4	22.8	23.4	20.0	21.7	21.1	16.8	22.5	20.9	21.9	22.8	-0.3 (-1.1; 0.6)	2004-2022
<b>50-74</b>	<b>N</b>	2,358	2,391	2,367	2,328	2,492	2,564	2,556	2,684	2,611	2,602	3,520	2,825	2,709	2,621	2,450	2,431	2,157	2,432	2,329		
	<b>CR</b>	174.9	175.1	171.3	166.3	175.4	177.5	174.0	179.4	171.6	168.4	224.2	176.9	166.7	158.4	145.8	143.0	125.5	140.1	133.4		
	<b>ESR2013</b>	182.6	182.8	180.6	176.3	187.1	190.5	186.0	192.3	185.0	182.4	243.8	187.7	179.3	166.2	152.2	147.8	129.2	143.0	135.8	-1.7 (-2.5; -0.8)	2004-2022
																					1.4 (-0.3; 3.2)	2004-2013
																					-4.4 (-7.9; -0.8)	2014-2017
																					-5.0 (-8.3; -1.5)	2018-2022
<b>75+</b>	<b>N</b>	1,509	1,545	1,651	1,682	1,777	1,752	1,786	1,881	1,898	1,923	1,838	1,882	1,815	1,721	1,666	1,639	1,592	1,684	1,679		
	<b>CR</b>	514.8	510.4	525.7	516.3	527.7	507.0	504.5	520.7	514.2	511.3	479.3	480.7	459.8	435.9	419.4	405.6	385.0	404.7	389.4		
	<b>ESR2013</b>	522.1	514.7	534.9	510.6	524.7	503.3	495.4	520.3	513.6	502.8	475.7	482.6	455.0	427.9	411.2	395.8	379.1	401.8	387.5	-1.8 (-2.1; -1.6)	2004-2022
																					-0.3 (-0.9; 0.4)	2004-2012
																					-3.1 (-3.5; -2.6)	2013-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.



2.3.2. Colorectal cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
<b>15-39 N</b>	49	56	67	68	79	66	73	71	90	92	79	89	92	91	92	89	83	94	88		
<b>CR</b>	2.9	3.3	4.0	4.0	4.7	3.9	4.3	4.1	5.2	5.3	4.6	5.1	5.3	5.2	5.3	5.1	4.7	5.4	5.0		
<b>ESR2013</b>	2.9	3.3	4.0	4.0	4.7	3.9	4.3	4.2	5.3	5.5	4.7	5.2	5.4	5.3	5.3	5.1	4.8	5.4	5.1	2.7 (2.0; 3.5)	2004-2022
																				6.0 (4.1; 8.0)	2004-2012
																				0.2 (-1.3; 1.6)	2013-2022
<b>40-49 N</b>	126	162	169	169	143	152	149	153	169	153	154	158	157	135	127	133	134	153	162		
<b>CR</b>	16.2	20.6	21.3	21.2	17.9	19.1	18.7	19.2	21.3	19.4	19.7	20.5	20.7	18.0	17.0	17.8	18.0	20.5	21.7		
<b>ESR2013</b>	16.3	20.7	21.4	21.3	17.9	19.0	18.6	19.0	21.2	19.3	19.6	20.4	20.6	17.7	16.8	17.7	17.9	20.5	21.8	0.0 (-0.8; 0.8)	2004-2022
<b>50-74 N</b>	1,632	1,627	1,640	1,583	1,686	1,655	1,684	1,666	1,725	1,769	2,066	1,787	1,755	1,753	1,636	1,731	1,528	1,647	1,514		
<b>CR</b>	113.3	111.9	111.9	106.9	112.7	109.2	109.4	106.5	108.6	109.9	126.7	108.0	104.4	102.5	94.4	98.9	86.5	92.4	84.6		
<b>ESR2013</b>	112.3	111.4	112.6	108.6	115.2	111.6	112.7	110.3	112.4	114.0	132.1	111.2	108.4	104.7	95.6	99.5	86.6	92.0	84.1	-1.5 (-2.0; -0.9)	2004-2022
																				0.7 (-0.4; 1.8)	2004-2013
																				-2.6 (-4.9; -0.3)	2014-2017
																				-4.3 (-6.5; -2.1)	2018-2022
<b>75+ N</b>	1,697	1,616	1,703	1,819	1,804	1,856	1,828	1,864	1,909	1,875	1,826	1,815	1,763	1,670	1,729	1,754	1,590	1,582	1,668		
<b>CR</b>	326.4	304.3	312.8	326.3	316.7	320.9	311.6	314.2	318.2	310.2	299.2	294.1	286.0	272.7	282.9	285.6	256.2	255.6	263.1		
<b>ESR2013</b>	325.7	306.9	311.8	323.1	313.0	316.5	305.5	309.6	312.7	303.8	294.5	288.2	278.6	264.0	271.0	275.8	249.0	247.5	258.7	-1.4 (-1.6; -1.1)	2004-2022
																				-0.3 (-1.0; 0.4)	2004-2011
																				-2.0 (-2.5; -1.6)	2012-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.



#### 3.1. Colorectal cancer prevalence: by region

3.1.1. Colorectal cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022

Region		Males				Females			
		1-year	5-year	10-year	15-year	1-year	5-year	10-year	15-year
Belgium	<b>N</b>	3,654	14,602	25,981	32,759	2,978	12,171	21,432	27,544
	<b>CR</b>	63.4	253.4	450.9	569	50.2	205.0	361.0	464
	<b>ESR2013</b>	67.5	270.6	485.0	615.3	45.8	186.1	326.0	415.7
Brussels	<b>N</b>	268	992	1,639	2,049	230	916	1,561	2,007
	<b>CR</b>	44.1	163.1	269.5	336.9	36.3	144.7	246.6	317.1
	<b>ESR2013</b>	68.3	254.1	429.0	542.2	44.1	175.4	298.9	382.7
Flanders	<b>N</b>	2,137	8,862	16,677	21,252	1,723	7,343	13,409	17,302
	<b>CR</b>	63.7	264.4	497.5	633.9	50.3	214.6	391.8	505.5
	<b>ESR2013</b>	63.4	262.8	495.9	634.3	43.7	184.5	335.7	429.3
Wallonia	<b>N</b>	1,249	4,748	7,665	9,458	1,025	3,912	6,462	8,235
	<b>CR</b>	69.4	263.7	425.6	525.2	54.5	208.0	343.6	437.9
	<b>ESR2013</b>	75.7	289.7	473.4	589.3	50.3	191.1	313.5	397.3

## 4. CANCER SURVIVAL



### 4.1. Colorectal cancer survival: by region

#### 4.1.1. Colorectal cancer survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	All	80,114	86.1% (85.8%; 86.3%)	75.7% (75.3%; 76.1%)	71.2% (70.6%; 71.7%)	67.2% (65.6%; 68.7%)
Males						
Belgium	All ages	44,371	86.7% (86.3%; 87.1%)	76.2% (75.7%; 76.7%)	70.9% (70.3%; 71.6%)	66.0% (64.2%; 67.8%)
	15-49	2,370	94.7% (93.8%; 95.6%)	82.6% (81.1%; 84.3%)	76.1% (74.2%; 78.1%)	70.6% (68.2%; 73.1%)
	50-74	25,314	90.7% (90.3%; 91.1%)	80.4% (79.8%; 81.0%)	74.6% (73.9%; 75.3%)	69.9% (68.8%; 71.1%)
	75+	16,725	79.5% (78.7%; 80.2%)	68.9% (67.9%; 70.0%)	64.7% (63.2%; 66.2%)	59.2% (54.8%; 63.9%)
Brussels	All ages	3,006	83.2% (81.7%; 84.7%)	70.5% (68.4%; 72.6%)	64.9% (62.3%; 67.6%)	56.5% (48.7%; 65.7%)
	15-49	272	92.4% (89.2%; 95.6%)	75.0% (69.8%; 80.7%)	64.4% (58.3%; 71.2%)	54.9% (46.7%; 64.6%)
	50-74	1,638	86.7% (84.9%; 88.4%)	75.5% (73.2%; 77.9%)	67.4% (64.6%; 70.3%)	59.0% (54.4%; 64.0%)
	75+	1,097	75.7% (72.8%; 78.8%)	61.8% (57.7%; 66.2%)	61.0% (55.4%; 67.0%)	52.5% (35.6%; 77.5%)
Flanders	All ages	27,693	88.2% (87.8%; 88.7%)	79.1% (78.5%; 79.8%)	75.1% (74.2%; 76.0%)	72.6% (70.4%; 74.8%)
	15-49	1,311	96.0% (94.9%; 97.1%)	84.7% (82.6%; 86.8%)	78.8% (76.3%; 81.3%)	73.8% (70.8%; 76.9%)
	50-74	15,533	92.4% (91.9%; 92.9%)	83.7% (83.0%; 84.4%)	79.0% (78.1%; 79.8%)	76.7% (75.2%; 78.2%)
	75+	10,876	81.4% (80.4%; 82.3%)	72.0% (70.6%; 73.3%)	69.1% (67.3%; 71.0%)	66.4% (60.8%; 72.4%)
Wallonia	All ages	13,674	84.3% (83.7%; 85.0%)	71.4% (70.5%; 72.4%)	63.6% (62.4%; 64.8%)	53.3% (50.2%; 56.5%)

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	<b>15-49</b>	787	93.4% (91.6%; 95.2%)	81.8% (79.1%; 84.7%)	75.7% (72.5%; 79.0%)	70.7% (66.5%; 75.0%)
	<b>50-74</b>	8,144	88.3% (87.6%; 89.1%)	75.0% (73.9%; 76.1%)	67.3% (66.0%; 68.5%)	57.3% (55.3%; 59.4%)
	<b>75+</b>	4,753	76.0% (74.6%; 77.4%)	63.6% (61.7%; 65.6%)	55.3% (52.7%; 58.0%)	43.6% (36.6%; 52.0%)
Females						
<b>Belgium</b>	<b>All ages</b>	35,743	85.3% (84.9%; 85.7%)	75.0% (74.5%; 75.6%)	71.4% (70.7%; 72.2%)	68.7% (66.0%; 71.5%)
	<b>15-49</b>	2,321	94.7% (93.7%; 95.6%)	84.5% (83.0%; 86.1%)	79.4% (77.7%; 81.2%)	75.1% (72.8%; 77.4%)
	<b>50-74</b>	16,733	91.0% (90.5%; 91.4%)	80.6% (80.0%; 81.3%)	75.9% (75.1%; 76.7%)	72.6% (71.4%; 73.8%)
	<b>75+</b>	16,721	78.3% (77.6%; 79.0%)	68.1% (67.1%; 69.2%)	65.9% (64.5%; 67.3%)	64.0% (58.4%; 70.1%)
Brussels	<b>All ages</b>	2,793	82.2% (80.7%; 83.8%)	72.2% (70.0%; 74.4%)	67.9% (65.0%; 70.8%)	70.2% (51.4%; 95.9%)
	<b>15-49</b>	249	92.8% (89.6%; 96.1%)	79.6% (74.6%; 85.0%)	77.0% (71.6%; 82.8%)	71.4% (64.3%; 79.3%)
	<b>50-74</b>	1,260	89.7% (87.9%; 91.4%)	77.7% (75.3%; 80.3%)	70.9% (68.0%; 73.9%)	65.9% (61.7%; 70.3%)
	<b>75+</b>	1,284	72.9% (70.1%; 75.8%)	65.2% (61.5%; 69.2%)	63.1% (57.9%; 68.8%)	73.8% (42.0%; 129.6%)
Flanders	<b>All ages</b>	21,694	86.9% (86.4%; 87.4%)	77.7% (76.9%; 78.4%)	75.1% (74.1%; 76.1%)	72.9% (70.3%; 75.7%)
	<b>15-49</b>	1,372	95.3% (94.2%; 96.4%)	86.0% (84.1%; 87.9%)	80.9% (78.7%; 83.2%)	76.9% (74.1%; 79.8%)
	<b>50-74</b>	9,973	92.4% (91.9%; 93.0%)	83.3% (82.5%; 84.2%)	79.8% (78.8%; 80.7%)	78.5% (77.0%; 80.0%)
	<b>75+</b>	10,365	80.5% (79.6%; 81.4%)	71.1% (69.8%; 72.4%)	69.9% (68.1%; 71.7%)	67.0% (61.5%; 72.9%)
Wallonia	<b>All ages</b>	11,257	82.8% (82.1%; 83.6%)	70.7% (69.6%; 71.7%)	65.1% (63.8%; 66.5%)	59.7% (55.5%; 64.3%)
	<b>15-49</b>	700	94.1% (92.3%; 95.9%)	83.4% (80.6%; 86.3%)	77.5% (74.2%; 80.9%)	72.8% (68.7%; 77.1%)
	<b>50-74</b>	5,500	88.6% (87.7%; 89.5%)	76.4% (75.2%; 77.6%)	69.8% (68.4%; 71.3%)	62.2% (60.1%; 64.5%)
	<b>75+</b>	5,072	75.1% (73.7%; 76.4%)	62.8% (60.9%; 64.6%)	58.3% (55.9%; 60.8%)	55.0% (46.7%; 64.8%)

## 4.2. Colorectal cancer survival: by sub-location and tumour stage

### 4.2.1. Colorectal cancer survival by sub-location, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022

		Net Survival Probability, 2013-2022							
location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
<b>Total</b>		80,114	86.1% (85.8%; 86.3%)	79.7% (79.4%; 80.1%)	75.7% (75.3%; 76.1%)	72.9% (72.4%; 73.3%)	71.2% (70.6%; 71.7%)	67.2% (65.6%; 68.7%)	
<b>Males</b>									
<b>CRC</b>	<b>All</b>	44,371	86.7% (86.3%; 87.1%)	80.3% (79.9%; 80.8%)	76.2% (75.7%; 76.7%)	73.0% (72.4%; 73.6%)	70.9% (70.3%; 71.6%)	66.0% (64.2%; 67.8%)	
	<b>I</b>	6,573	96.2% (95.5%; 96.9%)	95.0% (94.1%; 96.0%)	94.1% (92.9%; 95.3%)	92.9% (91.5%; 94.4%)	92.4% (90.7%; 94.2%)	93.9% (88.1%; 100.0%)	
	<b>II</b>	6,057	92.3% (91.5%; 93.2%)	89.1% (87.9%; 90.3%)	85.7% (84.3%; 87.2%)	82.8% (81.1%; 84.6%)	81.0% (78.9%; 83.1%)	73.3% (67.0%; 80.3%)	
	<b>III</b>	8,854	93.8% (93.1%; 94.4%)	89.2% (88.3%; 90.1%)	86.2% (85.1%; 87.3%)	82.7% (81.4%; 84.0%)	80.4% (78.9%; 81.9%)	75.0% (71.3%; 78.8%)	
	<b>IV</b>	8,149	62.1% (61.0%; 63.2%)	41.9% (40.8%; 43.1%)	29.7% (28.6%; 30.9%)	22.0% (20.9%; 23.1%)	17.5% (16.5%; 18.6%)	10.3% (9.0%; 11.8%)	
	<b>X/NA</b>	15,442	89.3% (88.8%; 89.9%)	85.7% (85.0%; 86.4%)	83.2% (82.4%; 84.1%)	81.2% (80.2%; 82.2%)	79.7% (78.6%; 80.8%)	74.5% (71.7%; 77.5%)	
Colon	<b>All</b>	30,784	85.9% (85.5%; 86.4%)	79.6% (79.1%; 80.2%)	75.8% (75.1%; 76.4%)	72.8% (72.1%; 73.6%)	71.0% (70.2%; 71.9%)	65.6% (63.4%; 68.0%)	
	<b>I</b>	4,202	96.4% (95.5%; 97.3%)	95.6% (94.5%; 96.8%)	94.8% (93.3%; 96.3%)	93.4% (91.6%; 95.3%)	92.5% (90.3%; 94.8%)	93.4% (86.3%; 101.0%)	
	<b>II</b>	4,155	93.0% (92.0%; 94.1%)	90.4% (89.0%; 91.8%)	87.5% (85.8%; 89.3%)	85.9% (83.8%; 88.1%)	84.2% (81.6%; 86.9%)	72.8% (63.9%; 83.0%)	
	<b>III</b>	3,895	92.4% (91.3%; 93.4%)	87.6% (86.2%; 89.0%)	84.6% (82.9%; 86.4%)	81.2% (79.2%; 83.3%)	79.5% (77.1%; 82.0%)	78.6% (72.2%; 85.6%)	
	<b>IV</b>	5,752	59.2% (57.9%; 60.6%)	39.1% (37.7%; 40.5%)	27.5% (26.2%; 28.8%)	20.3% (19.1%; 21.6%)	16.1% (15.0%; 17.4%)	9.4% (7.8%; 11.3%)	
	<b>X/NA</b>	13,130	90.1% (89.4%; 90.7%)	86.5% (85.7%; 87.3%)	84.2% (83.3%; 85.2%)	82.2% (81.1%; 83.3%)	80.9% (79.7%; 82.1%)	74.8% (71.6%; 78.1%)	
Rectum	<b>All</b>	14,167	88.3% (87.7%; 88.9%)	81.6% (80.8%; 82.4%)	76.8% (75.9%; 77.7%)	72.8% (71.7%; 73.8%)	70.3% (69.1%; 71.5%)	66.7% (64.2%; 69.4%)	
	<b>I</b>	2,400	95.5% (94.4%; 96.7%)	93.7% (92.2%; 95.3%)	92.5% (90.6%; 94.5%)	91.5% (89.2%; 93.9%)	91.6% (88.8%; 94.5%)	93.8% (84.4%; 104.3%)	
	<b>II</b>	1,921	90.9% (89.3%; 92.5%)	86.3% (84.3%; 88.5%)	82.1% (79.6%; 84.6%)	76.6% (73.6%; 79.7%)	74.4% (71.1%; 77.9%)	73.7% (67.4%; 80.6%)	
	<b>III</b>	4,999	94.8% (94.0%; 95.6%)	90.3% (89.2%; 91.4%)	87.3% (85.9%; 88.7%)	83.8% (82.1%; 85.4%)	81.1% (79.3%; 83.0%)	73.2% (68.9%; 77.8%)	
	<b>IV</b>	2,434	68.9% (67.0%; 70.9%)	48.6% (46.5%; 50.8%)	35.1% (33.0%; 37.3%)	26.0% (24.0%; 28.1%)	21.0% (19.1%; 23.1%)	12.4% (10.3%; 15.0%)	
	<b>X/NA</b>	2,422	85.4% (83.8%; 87.0%)	81.1% (79.2%; 83.0%)	77.4% (75.2%; 79.6%)	75.2% (72.7%; 77.7%)	72.6% (69.9%; 75.5%)	73.7% (68.5%; 79.3%)	

Net Survival Probability, 2013-2022									
location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
<b>Females</b>									
<b>CRC</b>	<b>All</b>	35,743	85.3% (84.9%; 85.7%)	79.0% (78.5%; 79.5%)	75.0% (74.5%; 75.6%)	72.8% (72.1%; 73.5%)	71.4% (70.7%; 72.2%)	68.7% (66.0%; 71.5%)	
	<b>I</b>	4,820	96.8% (96.0%; 97.5%)	95.9% (94.9%; 96.9%)	95.1% (93.8%; 96.4%)	94.6% (93.1%; 96.2%)	94.1% (92.2%; 96.1%)	91.5% (84.7%; 98.8%)	
	<b>II</b>	5,071	91.3% (90.3%; 92.3%)	88.4% (87.1%; 89.6%)	85.1% (83.6%; 86.7%)	83.4% (81.6%; 85.3%)	81.5% (79.2%; 83.8%)	78.7% (71.6%; 86.5%)	
	<b>III</b>	6,904	91.6% (90.8%; 92.4%)	87.2% (86.1%; 88.2%)	83.8% (82.6%; 85.1%)	81.8% (80.4%; 83.3%)	81.9% (80.3%; 83.6%)	78.2% (67.8%; 90.3%)	
	<b>IV</b>	6,139	57.4% (56.1%; 58.7%)	37.7% (36.5%; 39.0%)	26.7% (25.5%; 27.9%)	20.8% (19.6%; 22.0%)	17.2% (16.1%; 18.4%)	12.0% (10.5%; 13.7%)	
	<b>X/NA</b>	13,296	88.4% (87.8%; 89.1%)	84.0% (83.2%; 84.8%)	81.6% (80.7%; 82.5%)	80.0% (78.9%; 81.0%)	78.8% (77.6%; 80.0%)	76.8% (73.6%; 80.2%)	
Colon	<b>All</b>	27,287	84.7% (84.2%; 85.2%)	78.4% (77.8%; 79.0%)	74.9% (74.2%; 75.6%)	72.9% (72.1%; 73.7%)	71.8% (70.9%; 72.7%)	70.1% (66.7%; 73.6%)	
	<b>I</b>	3,417	96.5% (95.5%; 97.4%)	95.7% (94.5%; 97.0%)	95.3% (93.7%; 96.9%)	95.3% (93.5%; 97.3%)	95.2% (92.8%; 97.6%)	100.5% (92.1%; 109.6%)	
	<b>II</b>	3,937	91.6% (90.5%; 92.7%)	89.1% (87.6%; 90.5%)	86.2% (84.5%; 88.0%)	84.7% (82.6%; 86.9%)	82.7% (80.1%; 85.5%)	81.5% (72.8%; 91.3%)	
	<b>III</b>	3,756	89.8% (88.6%; 91.0%)	85.7% (84.2%; 87.2%)	82.8% (81.0%; 84.6%)	81.5% (79.5%; 83.7%)	83.3% (80.9%; 85.8%)	76.7% (57.0%; 103.2%)	
	<b>IV</b>	4,788	56.1% (54.6%; 57.6%)	36.0% (34.6%; 37.5%)	25.4% (24.0%; 26.8%)	20.0% (18.7%; 21.4%)	16.9% (15.6%; 18.2%)	12.0% (10.2%; 14.0%)	
	<b>X/NA</b>	11,697	89.0% (88.3%; 89.7%)	84.8% (83.9%; 85.6%)	82.7% (81.8%; 83.7%)	81.1% (80.0%; 82.3%)	80.0% (78.8%; 81.4%)	78.5% (74.9%; 82.2%)	
Rectum	<b>All</b>	8,743	87.1% (86.3%; 87.9%)	80.5% (79.5%; 81.5%)	75.4% (74.2%; 76.5%)	72.2% (70.9%; 73.5%)	70.0% (68.6%; 71.4%)	64.0% (61.0%; 67.2%)	
	<b>I</b>	1,412	97.6% (96.3%; 98.8%)	96.3% (94.5%; 98.0%)	94.7% (92.5%; 96.9%)	93.1% (90.4%; 96.0%)	91.9% (88.5%; 95.3%)	74.1% (63.5%; 86.5%)	
	<b>II</b>	1,144	90.3% (88.2%; 92.4%)	85.9% (83.3%; 88.7%)	81.4% (78.1%; 84.7%)	79.2% (75.5%; 83.0%)	77.3% (73.0%; 81.8%)	69.5% (60.4%; 80.0%)	
	<b>III</b>	3,159	93.8% (92.7%; 94.8%)	88.9% (87.5%; 90.3%)	85.1% (83.5%; 86.8%)	82.2% (80.3%; 84.2%)	80.7% (78.5%; 82.9%)	78.9% (74.0%; 84.0%)	
	<b>IV</b>	1,365	62.0% (59.4%; 64.8%)	43.6% (40.9%; 46.4%)	31.2% (28.6%; 34.0%)	23.4% (21.0%; 26.1%)	18.6% (16.3%; 21.2%)	11.9% (9.2%; 15.5%)	
	<b>X/NA</b>	1,666	84.1% (82.2%; 86.2%)	77.6% (75.3%; 80.1%)	72.9% (70.3%; 75.7%)	70.9% (68.0%; 73.9%)	68.7% (65.5%; 72.0%)	64.2% (58.5%; 70.5%)	

4.2.2. Colorectal cancer survival by sub-location, pathological stage ((y)pStage) and sex: number at risk and net survival probabilities, 2013-2022

		Net Survival Probability, 2013-2022							
location	(y)pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
<b>Total</b>		80,114	86.1% (85.8%; 86.3%)	79.7% (79.4%; 80.1%)	75.7% (75.3%; 76.1%)	72.9% (72.4%; 73.3%)	71.2% (70.6%; 71.7%)	67.2% (65.6%; 68.7%)	
<b>Males</b>									
<b>CRC</b>	<b>All</b>	44,371	86.7% (86.3%; 87.1%)	80.3% (79.9%; 80.8%)	76.2% (75.7%; 76.7%)	73.0% (72.4%; 73.6%)	70.9% (70.3%; 71.6%)	66.0% (64.2%; 67.8%)	
	<b>I</b>	11,530	98.0% (97.6%; 98.5%)	97.8% (97.2%; 98.4%)	97.5% (96.8%; 98.3%)	97.0% (96.1%; 98.0%)	96.8% (95.7%; 98.0%)	96.4% (92.9%; 100.0%)	
	<b>II</b>	11,076	95.3% (94.7%; 95.8%)	93.6% (92.8%; 94.4%)	92.4% (91.4%; 93.4%)	90.3% (89.1%; 91.5%)	89.2% (87.7%; 90.6%)	80.3% (75.6%; 85.3%)	
	<b>III</b>	11,106	90.6% (89.9%; 91.2%)	83.1% (82.3%; 84.0%)	77.1% (76.0%; 78.1%)	72.2% (70.9%; 73.4%)	68.4% (67.1%; 69.8%)	62.0% (58.9%; 65.4%)	
	<b>IV</b>	2,874	73.7% (72.0%; 75.4%)	54.4% (52.5%; 56.4%)	42.1% (40.1%; 44.1%)	33.4% (31.4%; 35.5%)	26.8% (24.9%; 28.9%)	16.0% (13.4%; 19.2%)	
	<b>X/NA</b>	8,643	59.9% (58.9%; 61.1%)	44.9% (43.7%; 46.0%)	36.6% (35.5%; 37.9%)	32.2% (30.9%; 33.5%)	30.2% (28.9%; 31.6%)	27.7% (25.7%; 30.0%)	
<i>Colon</i>	<b>All</b>	30,784	85.9% (85.5%; 86.4%)	79.6% (79.1%; 80.2%)	75.8% (75.1%; 76.4%)	72.8% (72.1%; 73.6%)	71.0% (70.2%; 71.9%)	65.6% (63.4%; 68.0%)	
	<b>I</b>	7,461	97.7% (97.2%; 98.3%)	97.7% (96.9%; 98.5%)	97.2% (96.2%; 98.2%)	96.8% (95.6%; 98.0%)	96.5% (95.0%; 98.0%)	94.6% (90.4%; 99.1%)	
	<b>II</b>	8,776	94.9% (94.2%; 95.6%)	93.5% (92.6%; 94.4%)	92.7% (91.6%; 93.8%)	91.1% (89.8%; 92.5%)	90.5% (88.9%; 92.2%)	80.7% (75.0%; 86.8%)	
	<b>III</b>	8,361	89.3% (88.6%; 90.1%)	81.6% (80.6%; 82.7%)	75.8% (74.6%; 77.0%)	71.5% (70.1%; 72.9%)	68.2% (66.6%; 69.8%)	62.8% (59.0%; 66.9%)	
	<b>IV</b>	2,340	71.6% (69.7%; 73.6%)	52.0% (49.8%; 54.3%)	39.6% (37.4%; 41.9%)	31.3% (29.1%; 33.6%)	25.2% (23.1%; 27.5%)	15.5% (12.5%; 19.2%)	
	<b>X/NA</b>	4,369	48.9% (47.3%; 50.5%)	32.1% (30.6%; 33.6%)	24.4% (22.9%; 25.9%)	20.1% (18.6%; 21.6%)	18.3% (16.8%; 19.9%)	16.0% (13.8%; 18.5%)	
<i>Rectum</i>	<b>All</b>	14,167	88.3% (87.7%; 88.9%)	81.6% (80.8%; 82.4%)	76.8% (75.9%; 77.7%)	72.8% (71.7%; 73.8%)	70.3% (69.1%; 71.5%)	66.7% (64.2%; 69.4%)	
	<b>I</b>	4,161	98.6% (97.9%; 99.2%)	97.8% (96.9%; 98.8%)	98.1% (96.9%; 99.3%)	97.3% (95.8%; 98.8%)	97.2% (95.4%; 99.1%)	99.4% (93.6%; 105.6%)	
	<b>II</b>	2,328	96.8% (95.7%; 97.9%)	94.1% (92.5%; 95.6%)	91.4% (89.5%; 93.4%)	87.3% (84.9%; 89.7%)	84.2% (81.5%; 87.1%)	78.6% (72.2%; 85.6%)	
	<b>III</b>	2,784	94.1% (93.0%; 95.3%)	87.6% (86.0%; 89.2%)	80.9% (79.0%; 82.9%)	74.0% (71.7%; 76.4%)	69.0% (66.5%; 71.7%)	59.3% (54.1%; 65.1%)	
	<b>IV</b>	555	82.4% (79.1%; 85.9%)	65.1% (60.9%; 69.5%)	52.1% (47.6%; 57.0%)	42.1% (37.5%; 47.2%)	33.4% (28.9%; 38.6%)	19.1% (14.0%; 26.2%)	
	<b>X/NA</b>	4,347	71.0% (69.6%; 72.5%)	57.6% (56.0%; 59.3%)	48.9% (47.1%; 50.7%)	44.2% (42.3%; 46.2%)	42.1% (40.0%; 44.3%)	39.7% (36.4%; 43.2%)	
<b>Females</b>									
<b>CRC</b>	<b>All</b>	35,743	85.3% (84.9%; 85.7%)	79.0% (78.5%; 79.5%)	75.0% (74.5%; 75.6%)	72.8% (72.1%; 73.5%)	71.4% (70.7%; 72.2%)	68.7% (66.0%; 71.5%)	

		Net Survival Probability, 2013-2022							
location	(y)pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
	<b>I</b>	8,215	98.9% (98.4%; 99.3%)	98.5% (97.9%; 99.2%)	98.2% (97.4%; 99.1%)	98.1% (97.1%; 99.2%)	98.1% (96.8%; 99.4%)	98.4% (94.4%; 102.4%)	
	<b>II</b>	9,588	95.6% (95.0%; 96.2%)	95.0% (94.3%; 95.8%)	94.1% (93.1%; 95.1%)	93.2% (92.0%; 94.4%)	92.5% (91.0%; 94.1%)	90.7% (85.1%; 96.8%)	
	<b>III</b>	9,187	88.9% (88.1%; 89.6%)	80.8% (79.8%; 81.8%)	75.1% (73.9%; 76.2%)	71.7% (70.4%; 73.0%)	69.8% (68.3%; 71.2%)	63.7% (57.0%; 71.3%)	
	<b>IV</b>	2,746	69.9% (68.1%; 71.7%)	51.4% (49.5%; 53.5%)	40.0% (38.0%; 42.0%)	33.2% (31.2%; 35.2%)	27.6% (25.6%; 29.7%)	19.6% (17.2%; 22.3%)	
	<b>X/NA</b>	6,608	54.9% (53.6%; 56.2%)	39.9% (38.6%; 41.3%)	32.6% (31.3%; 34.0%)	29.1% (27.8%; 30.5%)	27.4% (26.0%; 28.9%)	26.0% (23.5%; 28.8%)	
<i>Colon</i>	<b>All</b>	27,287	84.7% (84.2%; 85.2%)	78.4% (77.8%; 79.0%)	74.9% (74.2%; 75.6%)	72.9% (72.1%; 73.7%)	71.8% (70.9%; 72.7%)	70.1% (66.7%; 73.6%)	
	<b>I</b>	5,803	98.6% (98.1%; 99.2%)	98.3% (97.5%; 99.1%)	98.2% (97.1%; 99.2%)	98.0% (96.7%; 99.3%)	97.9% (96.3%; 99.5%)	99.4% (94.6%; 104.3%)	
	<b>II</b>	8,200	95.5% (94.9%; 96.2%)	95.1% (94.3%; 96.0%)	94.4% (93.3%; 95.5%)	93.9% (92.6%; 95.3%)	93.7% (92.0%; 95.4%)	93.1% (86.6%; 100.1%)	
	<b>III</b>	7,494	87.7% (86.8%; 88.5%)	79.2% (78.1%; 80.3%)	73.9% (72.7%; 75.2%)	71.0% (69.5%; 72.5%)	69.5% (67.9%; 71.2%)	64.3% (56.2%; 73.6%)	
	<b>IV</b>	2,385	68.5% (66.6%; 70.5%)	49.6% (47.5%; 51.8%)	38.7% (36.6%; 40.9%)	32.2% (30.1%; 34.4%)	26.8% (24.7%; 29.0%)	19.1% (16.6%; 22.1%)	
	<b>X/NA</b>	3,823	44.7% (43.1%; 46.4%)	28.8% (27.2%; 30.4%)	21.9% (20.4%; 23.5%)	18.7% (17.2%; 20.3%)	17.5% (16.0%; 19.2%)	18.1% (15.3%; 21.5%)	
<i>Rectum</i>	<b>All</b>	8,743	87.1% (86.3%; 87.9%)	80.5% (79.5%; 81.5%)	75.4% (74.2%; 76.5%)	72.2% (70.9%; 73.5%)	70.0% (68.6%; 71.4%)	64.0% (61.0%; 67.2%)	
	<b>I</b>	2,451	99.5% (98.8%; 100.2%)	99.1% (98.0%; 100.1%)	98.5% (97.1%; 99.9%)	98.5% (96.8%; 100.3%)	98.6% (96.4%; 100.8%)	96.3% (89.7%; 103.4%)	
	<b>II</b>	1,400	96.1% (94.7%; 97.5%)	94.7% (92.9%; 96.6%)	92.5% (90.2%; 94.9%)	88.9% (86.1%; 91.8%)	85.9% (82.5%; 89.3%)	77.9% (69.8%; 87.0%)	
	<b>III</b>	1,712	94.2% (92.9%; 95.6%)	87.9% (86.0%; 89.8%)	80.0% (77.6%; 82.4%)	74.5% (71.8%; 77.4%)	70.7% (67.6%; 74.0%)	60.5% (54.3%; 67.4%)	
	<b>IV</b>	365	79.0% (74.8%; 83.5%)	62.9% (57.9%; 68.4%)	48.4% (43.2%; 54.1%)	40.0% (34.8%; 46.0%)	33.2% (28.1%; 39.3%)	22.8% (17.2%; 30.3%)	
	<b>X/NA</b>	2,819	68.6% (66.8%; 70.5%)	55.0% (52.9%; 57.1%)	47.2% (45.0%; 49.4%)	43.4% (41.1%; 45.8%)	41.1% (38.7%; 43.7%)	35.9% (31.9%; 40.4%)	



4.2.3. Colorectal cancer survival by sub-location, stage and sex: number at risk and net survival probabilities, 2013-2022

		Net Survival Probability, 2013-2022							
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
<b>Total</b>		80,114	86.1% (85.8%; 86.3%)	79.7% (79.4%; 80.1%)	75.7% (75.3%; 76.1%)	72.9% (72.4%; 73.3%)	71.2% (70.6%; 71.7%)	67.2% (65.6%; 68.7%)	
<b>Males</b>									
<b>CRC</b>	<b>All</b>	44,371	86.7% (86.3%; 87.1%)	80.3% (79.9%; 80.8%)	76.2% (75.7%; 76.7%)	73.0% (72.4%; 73.6%)	70.9% (70.3%; 71.6%)	66.0% (64.2%; 67.8%)	
	<b>I</b>	10,960	96.8% (96.3%; 97.3%)	96.1% (95.5%; 96.8%)	95.5% (94.6%; 96.3%)	94.9% (93.8%; 95.9%)	94.7% (93.4%; 96.0%)	93.9% (90.2%; 97.6%)	
	<b>II</b>	10,822	93.7% (93.1%; 94.3%)	92.2% (91.3%; 93.0%)	90.8% (89.8%; 91.8%)	89.1% (87.9%; 90.3%)	88.2% (86.7%; 89.7%)	80.4% (75.6%; 85.4%)	
	<b>III</b>	12,654	92.6% (92.0%; 93.2%)	87.3% (86.5%; 88.1%)	83.4% (82.4%; 84.3%)	79.5% (78.4%; 80.6%)	76.6% (75.4%; 77.9%)	71.4% (68.4%; 74.6%)	
	<b>IV</b>	8,914	62.8% (61.8%; 63.9%)	42.9% (41.8%; 44.0%)	30.8% (29.8%; 31.9%)	23.2% (22.1%; 24.2%)	18.7% (17.7%; 19.8%)	11.2% (9.9%; 12.7%)	
	<b>X/NA</b>	1,904	60.4% (58.0%; 62.8%)	49.6% (47.1%; 52.2%)	43.9% (41.3%; 46.7%)	40.5% (37.7%; 43.5%)	38.0% (35.1%; 41.2%)	35.7% (31.3%; 40.6%)	
<i>Colon</i>	<b>All</b>	30,784	85.9% (85.5%; 86.4%)	79.6% (79.1%; 80.2%)	75.8% (75.1%; 76.4%)	72.8% (72.1%; 73.6%)	71.0% (70.2%; 71.9%)	65.6% (63.4%; 68.0%)	
	<b>I</b>	7,652	96.9% (96.3%; 97.5%)	96.5% (95.7%; 97.3%)	96.0% (95.0%; 97.0%)	95.5% (94.3%; 96.8%)	95.4% (93.9%; 96.9%)	93.5% (89.3%; 97.9%)	
	<b>II</b>	8,586	94.4% (93.7%; 95.1%)	93.4% (92.5%; 94.3%)	92.8% (91.6%; 93.9%)	91.5% (90.2%; 92.9%)	91.0% (89.3%; 92.7%)	81.3% (75.6%; 87.5%)	
	<b>III</b>	7,391	91.2% (90.4%; 92.1%)	85.4% (84.3%; 86.5%)	81.0% (79.7%; 82.3%)	77.2% (75.7%; 78.7%)	74.3% (72.6%; 76.0%)	69.2% (65.0%; 73.6%)	
	<b>IV</b>	6,440	60.5% (59.2%; 61.8%)	40.6% (39.3%; 42.0%)	29.1% (27.8%; 30.3%)	22.0% (20.8%; 23.2%)	17.7% (16.5%; 18.9%)	10.7% (9.2%; 12.6%)	
	<b>X/NA</b>	1,242	59.3% (56.4%; 62.4%)	48.1% (45.1%; 51.4%)	43.3% (40.1%; 46.7%)	39.4% (36.0%; 43.1%)	36.9% (33.4%; 40.8%)	35.8% (30.2%; 42.5%)	
<i>Rectum</i>	<b>All</b>	14,167	88.3% (87.7%; 88.9%)	81.6% (80.8%; 82.4%)	76.8% (75.9%; 77.7%)	72.8% (71.7%; 73.8%)	70.3% (69.1%; 71.5%)	66.7% (64.2%; 69.4%)	
	<b>I</b>	3,390	96.4% (95.5%; 97.3%)	95.1% (93.8%; 96.3%)	94.2% (92.6%; 95.7%)	93.1% (91.2%; 95.0%)	92.7% (90.4%; 95.1%)	94.1% (87.2%; 101.6%)	
	<b>II</b>	2,274	91.2% (89.7%; 92.6%)	87.3% (85.4%; 89.2%)	83.5% (81.3%; 85.8%)	79.9% (77.3%; 82.6%)	77.6% (74.7%; 80.7%)	76.4% (70.1%; 83.3%)	
	<b>III</b>	5,319	94.5% (93.7%; 95.3%)	89.9% (88.8%; 91.0%)	86.6% (85.3%; 87.9%)	82.6% (81.0%; 84.2%)	79.8% (77.9%; 81.6%)	74.4% (70.3%; 78.7%)	
	<b>IV</b>	2,526	68.9% (67.0%; 70.8%)	48.8% (46.7%; 51.0%)	35.4% (33.4%; 37.5%)	26.3% (24.4%; 28.4%)	21.4% (19.5%; 23.4%)	12.6% (10.5%; 15.2%)	
	<b>X/NA</b>	668	62.3% (58.4%; 66.3%)	52.0% (47.9%; 56.5%)	44.7% (40.4%; 49.6%)	42.2% (37.5%; 47.6%)	39.7% (34.7%; 45.4%)	34.8% (28.8%; 42.0%)	
<b>Females</b>									
<b>CRC</b>	<b>All</b>	35,743	85.3% (84.9%; 85.7%)	79.0% (78.5%; 79.5%)	75.0% (74.5%; 75.6%)	72.8% (72.1%; 73.5%)	71.4% (70.7%; 72.2%)	68.7% (66.0%; 71.5%)	

Net Survival Probability, 2013-2022								
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	<b>I</b>	7,941	97.8% (97.3%; 98.4%)	97.1% (96.4%; 97.8%)	96.5% (95.5%; 97.4%)	96.1% (95.0%; 97.3%)	96.0% (94.6%; 97.4%)	95.8% (91.9%; 100.0%)
	<b>II</b>	9,589	93.6% (93.0%; 94.3%)	92.7% (91.9%; 93.6%)	91.7% (90.7%; 92.8%)	90.9% (89.6%; 92.2%)	90.1% (88.5%; 91.7%)	88.6% (82.9%; 94.6%)
	<b>III</b>	10,154	90.2% (89.5%; 90.9%)	84.3% (83.4%; 85.2%)	80.0% (78.9%; 81.0%)	77.2% (76.0%; 78.4%)	75.8% (74.4%; 77.1%)	71.7% (65.4%; 78.5%)
	<b>IV</b>	6,980	58.8% (57.6%; 60.0%)	39.3% (38.1%; 40.6%)	28.6% (27.4%; 29.7%)	22.8% (21.7%; 24.0%)	19.0% (17.9%; 20.2%)	13.4% (12.0%; 15.0%)
	<b>X/NA</b>	1,695	59.4% (56.9%; 62.0%)	46.4% (43.7%; 49.2%)	41.2% (38.4%; 44.2%)	38.4% (35.5%; 41.6%)	37.3% (34.2%; 40.6%)	33.7% (28.0%; 40.5%)
<i>Colon</i>	<b>All</b>	27,287	84.7% (84.2%; 85.2%)	78.4% (77.8%; 79.0%)	74.9% (74.2%; 75.6%)	72.9% (72.1%; 73.7%)	71.8% (70.9%; 72.7%)	70.1% (66.7%; 73.6%)
	<b>I</b>	5,986	97.8% (97.2%; 98.4%)	97.2% (96.4%; 98.1%)	96.7% (95.7%; 97.8%)	96.4% (95.1%; 97.8%)	96.2% (94.6%; 97.9%)	99.0% (94.4%; 103.8%)
	<b>II</b>	8,193	94.2% (93.5%; 94.9%)	93.7% (92.8%; 94.6%)	93.1% (92.0%; 94.2%)	92.8% (91.4%; 94.2%)	92.4% (90.7%; 94.2%)	92.1% (85.6%; 99.0%)
	<b>III</b>	6,815	88.5% (87.6%; 89.4%)	82.1% (81.0%; 83.3%)	78.0% (76.7%; 79.3%)	75.3% (73.8%; 76.8%)	74.1% (72.4%; 75.9%)	69.3% (60.5%; 79.4%)
	<b>IV</b>	5,560	57.8% (56.5%; 59.2%)	38.1% (36.8%; 39.5%)	27.8% (26.5%; 29.1%)	22.5% (21.2%; 23.8%)	18.9% (17.7%; 20.2%)	13.7% (12.1%; 15.5%)
	<b>X/NA</b>	1,154	57.4% (54.4%; 60.6%)	44.3% (41.1%; 47.7%)	39.7% (36.4%; 43.3%)	36.8% (33.3%; 40.5%)	36.2% (32.6%; 40.2%)	34.7% (27.8%; 43.3%)
<i>Rectum</i>	<b>All</b>	8,743	87.1% (86.3%; 87.9%)	80.5% (79.5%; 81.5%)	75.4% (74.2%; 76.5%)	72.2% (70.9%; 73.5%)	70.0% (68.6%; 71.4%)	64.0% (61.0%; 67.2%)
	<b>I</b>	1,985	98.1% (97.1%; 99.1%)	96.9% (95.5%; 98.3%)	95.7% (93.8%; 97.5%)	95.2% (93.0%; 97.5%)	95.1% (92.5%; 97.8%)	86.9% (79.4%; 95.2%)
	<b>II</b>	1,411	90.6% (88.8%; 92.5%)	86.8% (84.4%; 89.2%)	83.5% (80.8%; 86.4%)	79.8% (76.6%; 83.1%)	76.7% (73.0%; 80.6%)	68.7% (60.6%; 78.0%)
	<b>III</b>	3,366	93.6% (92.6%; 94.6%)	88.7% (87.4%; 90.1%)	83.9% (82.3%; 85.6%)	81.1% (79.2%; 83.0%)	79.0% (76.8%; 81.2%)	76.0% (71.4%; 81.0%)
	<b>IV</b>	1,437	62.6% (60.0%; 65.2%)	43.9% (41.2%; 46.6%)	31.6% (29.1%; 34.3%)	24.1% (21.7%; 26.8%)	19.5% (17.2%; 22.1%)	12.5% (9.9%; 15.9%)
	<b>X/NA</b>	549	63.2% (58.9%; 67.7%)	50.6% (45.9%; 55.7%)	43.8% (38.9%; 49.2%)	41.5% (36.4%; 47.4%)	39.1% (33.9%; 45.2%)	31.1% (23.1%; 42.0%)

## 5. CANCER SURVIVAL TRENDS



### 5.1. Colorectal cancer survival trends: by tumour stage

#### 5.1.1. Colorectal cancer survival trends by stage and sex: number at risk and net survival probabilities, 2008-2022

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
<b>2008-2012</b>	<b>All</b>	22,506	84.3% (83.8%; 84.8%)	71.3% (70.6%; 72.0%)	65.1% (64.2%; 66.0%)	18,341	83.1% (82.5%; 83.8%)	71.3% (70.5%; 72.1%)	66.7% (65.7%; 67.6%)
	<b>I</b>	3,912	95.4% (94.4%; 96.3%)	93.0% (91.6%; 94.5%)	90.8% (88.9%; 92.8%)	3,036	96.5% (95.6%; 97.5%)	95.4% (93.9%; 96.9%)	93.8% (91.7%; 95.9%)
	<b>II</b>	5,942	92.9% (92.1%; 93.8%)	88.3% (87.0%; 89.7%)	84.3% (82.5%; 86.1%)	5,194	92.0% (91.1%; 92.9%)	87.3% (85.9%; 88.7%)	85.1% (83.2%; 87.0%)
	<b>III</b>	6,595	90.3% (89.4%; 91.2%)	77.9% (76.6%; 79.2%)	71.1% (69.5%; 72.7%)	5,284	88.4% (87.4%; 89.4%)	76.4% (75.0%; 77.9%)	70.7% (69.0%; 72.4%)
	<b>IV</b>	4,250	63.9% (62.4%; 65.5%)	30.0% (28.6%; 31.6%)	17.1% (15.8%; 18.5%)	3,247	59.3% (57.6%; 61.1%)	27.9% (26.3%; 29.6%)	17.9% (16.5%; 19.4%)
	<b>X/NA</b>	2,234	62.4% (60.3%; 64.6%)	45.6% (43.2%; 48.0%)	40.9% (38.3%; 43.6%)	1,866	63.3% (61.0%; 65.7%)	48.3% (45.7%; 51.0%)	43.9% (41.1%; 46.8%)
<b>2013-2017</b>	<b>All</b>	23,878	87.2% (86.7%; 87.7%)	77.0% (76.3%; 77.7%)	71.7% (70.8%; 72.5%)	18,774	85.4% (84.8%; 86.0%)	74.8% (74.1%; 75.6%)	71.4% (70.5%; 72.4%)
	<b>I</b>	5,932	97.1% (96.4%; 97.7%)	96.4% (95.3%; 97.5%)	95.4% (93.8%; 97.0%)	4,111	98.2% (97.5%; 98.9%)	96.6% (95.4%; 97.9%)	96.2% (94.5%; 97.9%)
	<b>II</b>	5,837	93.8% (93.0%; 94.6%)	90.7% (89.4%; 92.0%)	87.6% (85.7%; 89.4%)	5,074	93.2% (92.3%; 94.1%)	91.4% (90.0%; 92.8%)	90.1% (88.2%; 92.1%)
	<b>III</b>	6,829	92.8% (92.0%; 93.6%)	84.0% (82.8%; 85.2%)	77.4% (75.8%; 78.9%)	5,349	90.1% (89.2%; 91.0%)	79.0% (77.6%; 80.5%)	75.0% (73.3%; 76.8%)
	<b>IV</b>	4,428	63.1% (61.6%; 64.6%)	30.7% (29.3%; 32.2%)	18.4% (17.2%; 19.8%)	3,388	59.8% (58.1%; 61.6%)	27.9% (26.3%; 29.5%)	18.3% (16.9%; 19.8%)
	<b>X/NA</b>	1,287	64.1% (61.4%; 67.0%)	47.2% (44.1%; 50.6%)	41.5% (38.1%; 45.2%)	1,139	59.3% (56.3%; 62.5%)	42.5% (39.2%; 46.0%)	38.8% (35.3%; 42.7%)
<b>2018-2022</b>	<b>All</b>	20,641	86.1% (85.6%; 86.7%)	75.1% (74.3%; 75.9%)	70.0% (68.8%; 71.2%)	17,080	85.1% (84.5%; 85.7%)	75.3% (74.4%; 76.2%)	71.1% (69.8%; 72.5%)
	<b>I</b>	5,048	96.4% (95.7%; 97.2%)	94.2% (92.8%; 95.6%)	93.9% (91.7%; 96.1%)	3,837	97.5% (96.7%; 98.3%)	96.3% (94.9%; 97.8%)	95.5% (93.0%; 98.1%)
	<b>II</b>	5,003	93.6% (92.7%; 94.6%)	91.0% (89.4%; 92.6%)	89.4% (86.8%; 92.2%)	4,526	94.2% (93.3%; 95.1%)	92.1% (90.5%; 93.7%)	89.2% (86.2%; 92.3%)

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	III	5,838	92.4% (91.5%; 93.2%)	82.4% (81.0%; 83.9%)	75.3% (73.1%; 77.7%)	4,816	90.3% (89.3%; 91.3%)	81.1% (79.6%; 82.7%)	76.5% (74.1%; 78.9%)
	IV	4,488	62.5% (61.0%; 64.0%)	30.9% (29.4%; 32.6%)	19.4% (17.7%; 21.2%)	3,594	57.8% (56.1%; 59.5%)	29.5% (27.9%; 31.3%)	20.3% (18.5%; 22.3%)
	X/NA	617	52.5% (48.4%; 57.0%)	36.9% (32.3%; 42.1%)	28.0% (21.9%; 35.9%)	558	59.3% (55.0%; 64.0%)	37.8% (32.8%; 43.6%)	33.0% (27.2%; 40.2%)

## 5.2. Colorectal cancer survival trends: by sub-location and tumour stage

### 5.2.1. Colorectal cancer survival trends by sub-location, stage and sex: number at risk and net survival probabilities, 2008-2022

Period	sub-location	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2008-2012	Colon	All	15,409	83.2% (82.5%; 83.8%)	70.2% (69.3%; 71.1%)	64.5% (63.5%; 65.6%)	13,732	82.5% (81.8%; 83.2%)	70.8% (69.8%; 71.7%)	66.8% (65.7%; 68.0%)
		I	2,622	95.0% (93.9%; 96.2%)	93.4% (91.6%; 95.2%)	91.3% (88.8%; 93.8%)	2,166	96.4% (95.3%; 97.6%)	95.2% (93.4%; 97.0%)	93.4% (90.9%; 95.9%)
		II	4,574	93.4% (92.5%; 94.4%)	89.7% (88.2%; 91.3%)	86.5% (84.5%; 88.6%)	4,277	92.4% (91.4%; 93.4%)	88.9% (87.4%; 90.5%)	87.6% (85.5%; 89.7%)
		III	3,839	88.2% (87.0%; 89.4%)	74.5% (72.8%; 76.3%)	67.7% (65.6%; 69.9%)	3,662	86.6% (85.3%; 87.9%)	73.5% (71.7%; 75.3%)	68.6% (66.5%; 70.7%)
		IV	3,058	62.0% (60.2%; 63.9%)	28.5% (26.8%; 30.3%)	16.4% (14.9%; 18.0%)	2,500	57.6% (55.6%; 59.7%)	26.1% (24.3%; 27.9%)	17.3% (15.8%; 19.0%)
		X/NA	1,579	61.4% (58.9%; 64.0%)	44.6% (41.8%; 47.5%)	39.8% (36.8%; 42.9%)	1,335	63.7% (61.0%; 66.5%)	48.9% (45.8%; 52.1%)	43.9% (40.6%; 47.4%)
	Rectum	All	7,336	86.7% (85.8%; 87.6%)	73.4% (72.1%; 74.6%)	66.1% (64.7%; 67.6%)	4,726	85.1% (84.0%; 86.2%)	72.9% (71.3%; 74.4%)	66.2% (64.4%; 68.0%)
		I	1,313	95.9% (94.5%; 97.5%)	92.4% (90.0%; 94.9%)	89.7% (86.5%; 92.9%)	878	96.7% (95.0%; 98.4%)	96.0% (93.3%; 98.8%)	94.6% (90.9%; 98.5%)
		II	1,381	91.4% (89.6%; 93.3%)	83.8% (81.1%; 86.6%)	76.9% (73.5%; 80.4%)	927	90.4% (88.1%; 92.7%)	79.9% (76.6%; 83.3%)	73.7% (69.8%; 77.8%)
		III	2,782	93.1% (91.9%; 94.3%)	82.3% (80.5%; 84.2%)	75.4% (73.2%; 77.8%)	1,634	92.5% (91.0%; 94.0%)	82.9% (80.6%; 85.3%)	75.2% (72.4%; 78.1%)
		IV	1,200	68.7% (66.0%; 71.6%)	33.9% (31.2%; 36.9%)	19.0% (16.7%; 21.6%)	754	65.1% (61.6%; 68.7%)	33.9% (30.5%; 37.7%)	19.8% (16.9%; 23.1%)
		X/NA	661	64.4% (60.5%; 68.4%)	47.4% (43.1%; 52.1%)	43.1% (38.5%; 48.3%)	537	62.5% (58.3%; 67.1%)	46.8% (42.2%; 51.9%)	43.8% (39.0%; 49.1%)
2013-2017	Colon	All	16,578	86.5% (85.9%; 87.1%)	76.6% (75.7%; 77.4%)	71.7% (70.7%; 72.8%)	14,292	84.7% (84.0%; 85.4%)	74.6% (73.7%; 75.5%)	71.5% (70.4%; 72.7%)
		I	4,173	97.5% (96.7%; 98.2%)	97.1% (95.9%; 98.4%)	96.2% (94.4%; 98.1%)	3,059	98.1% (97.3%; 98.9%)	96.7% (95.3%; 98.1%)	96.2% (94.2%; 98.2%)
		II	4,588	94.3% (93.4%; 95.2%)	92.3% (90.8%; 93.8%)	90.0% (87.9%; 92.1%)	4,323	93.7% (92.8%; 94.7%)	92.9% (91.4%; 94.4%)	92.4% (90.3%; 94.6%)
		III	4,010	91.8% (90.8%; 92.9%)	82.0% (80.4%; 83.7%)	75.7% (73.6%; 77.8%)	3,622	88.6% (87.4%; 89.8%)	77.2% (75.5%; 79.0%)	73.3% (71.2%; 75.6%)
		IV	3,216	60.7% (59.0%; 62.6%)	28.8% (27.2%; 30.6%)	17.3% (15.8%; 18.8%)	2,689	57.9% (56.0%; 59.8%)	26.4% (24.7%; 28.2%)	17.7% (16.2%; 19.4%)
		X/NA	863	63.2% (59.8%; 66.8%)	46.8% (42.9%; 50.9%)	40.3% (36.1%; 45.0%)	790	57.8% (54.2%; 61.7%)	40.9% (37.0%; 45.2%)	37.5% (33.4%; 42.1%)
	Rectum	All	7,580	88.6% (87.7%; 89.4%)	77.7% (76.5%; 78.9%)	71.1% (69.7%; 72.6%)	4,621	87.5% (86.5%; 88.6%)	75.5% (74.0%; 77.0%)	70.6% (68.8%; 72.4%)

Period	sub-location	Stage	Males				Females			
			Net Survival Probability			Net Survival Probability				
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		I	1,802	96.1% (94.8%; 97.4%)	94.7% (92.7%; 96.7%)	93.0% (90.1%; 96.0%)	1,064	98.4% (97.1%; 99.7%)	96.5% (94.2%; 98.9%)	96.5% (93.2%; 99.8%)
		II	1,264	91.9% (90.1%; 93.8%)	84.6% (81.8%; 87.6%)	78.6% (75.0%; 82.4%)	754	90.1% (87.6%; 92.6%)	82.8% (79.2%; 86.6%)	76.8% (72.3%; 81.5%)
		III	2,844	94.2% (93.1%; 95.3%)	86.9% (85.2%; 88.7%)	79.8% (77.6%; 82.1%)	1,741	93.1% (91.7%; 94.6%)	82.7% (80.5%; 84.9%)	78.5% (75.8%; 81.3%)
		IV	1,243	69.1% (66.5%; 71.9%)	35.5% (32.8%; 38.6%)	21.4% (19.0%; 24.2%)	709	67.5% (64.0%; 71.2%)	33.4% (29.9%; 37.3%)	20.3% (17.4%; 23.8%)
		X/NA	429	65.9% (61.3%; 71.0%)	47.6% (42.3%; 53.5%)	43.4% (37.8%; 49.8%)	355	62.2% (57.0%; 67.9%)	45.6% (39.9%; 52.2%)	41.5% (35.3%; 48.8%)
<b>2018-2022</b>	<b>Colon</b>	All	14,294	85.3% (84.6%; 85.9%)	74.7% (73.7%; 75.7%)	70.3% (68.8%; 71.8%)	13,070	84.6% (83.9%; 85.4%)	75.3% (74.3%; 76.3%)	71.9% (70.3%; 73.4%)
		I	3,492	96.3% (95.3%; 97.2%)	94.5% (92.8%; 96.2%)	94.5% (91.9%; 97.2%)	2,932	97.4% (96.5%; 98.4%)	96.9% (95.3%; 98.6%)	96.3% (93.3%; 99.4%)
		II	4,013	94.5% (93.5%; 95.5%)	93.3% (91.6%; 95.0%)	92.7% (89.7%; 95.9%)	3,880	94.7% (93.7%; 95.7%)	93.3% (91.6%; 95.1%)	91.6% (88.4%; 94.9%)
		III	3,385	90.6% (89.3%; 91.8%)	79.6% (77.6%; 81.6%)	71.8% (68.7%; 75.0%)	3,199	88.3% (87.0%; 89.6%)	79.0% (77.0%; 81.1%)	75.5% (72.6%; 78.5%)
		IV	3,226	60.2% (58.4%; 62.0%)	29.3% (27.5%; 31.2%)	18.6% (16.6%; 20.8%)	2,872	57.7% (55.9%; 59.6%)	29.3% (27.5%; 31.3%)	20.5% (18.5%; 22.7%)
		X/NA	379	50.5% (45.3%; 56.2%)	35.3% (29.7%; 41.9%)	27.8% (21.5%; 35.9%)	365	56.4% (51.2%; 62.3%)	36.8% (30.9%; 43.8%)	32.9% (25.8%; 42.0%)
	<b>Rectum</b>	All	6,589	88.1% (87.1%; 89.0%)	75.6% (74.2%; 77.0%)	69.0% (67.0%; 71.2%)	4,122	86.7% (85.5%; 87.9%)	75.3% (73.5%; 77.0%)	68.4% (65.9%; 71.0%)
		I	1,588	96.7% (95.4%; 98.0%)	93.3% (90.9%; 95.8%)	91.9% (88.1%; 96.0%)	921	97.7% (96.1%; 99.2%)	94.4% (91.5%; 97.3%)	92.7% (88.2%; 97.4%)
		II	1,010	90.2% (87.9%; 92.5%)	81.9% (78.3%; 85.7%)	76.3% (71.0%; 81.9%)	657	91.3% (88.6%; 94.0%)	84.3% (80.0%; 88.9%)	74.5% (67.0%; 82.7%)
		III	2,475	94.8% (93.7%; 96.0%)	86.1% (84.1%; 88.3%)	80.0% (76.7%; 83.4%)	1,625	94.2% (92.8%; 95.6%)	85.3% (82.9%; 87.8%)	78.0% (74.0%; 82.2%)
		IV	1,283	68.7% (66.0%; 71.4%)	35.2% (32.3%; 38.4%)	21.7% (18.7%; 25.2%)	728	57.7% (54.1%; 61.5%)	30.2% (26.7%; 34.1%)	19.5% (15.9%; 24.0%)
		X/NA	239	55.6% (49.3%; 62.8%)	39.1% (31.6%; 48.3%)	28.3% (17.6%; 45.4%)	194	65.0% (57.8%; 72.9%)	39.5% (31.0%; 50.2%)	33.2% (24.1%; 45.8%)

## 6. CANCER MORTALITY



### 6.1. Colorectal cancer mortality: by region

6.1.1. Colorectal cancer mortality\* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Males																						
<b>Belgium</b>	0	0	0	0	1	0	5	3	10	16	45	72	109	134	199	175	211	204	114	25	1,323	26.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.0]	[1.3]	[0.8]	[2.7]	[4.2]	[11.3]	[17.8]	[30.0]	[43.7]	[75.1]	[100.5]	[161.5]	[262.6]	[406.1]	[458.4]	[23.3]	(25.2; 28.2)
Brussels	0	0	0	0	0	0	0	1	0	2	5	4	7	14	18	18	11	22	8	0	110	31.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.1]	[0.0]	[4.6]	[12.5]	[11.7]	[25.6]	[67.4]	[107.8]	[156.6]	[130.1]	[435.3]	[367.8]	[0.0]	[18.4]	(25.7; 37.8)
Flanders	0	0	0	0	1	0	4	1	5	12	23	45	53	70	102	92	126	112	79	17	742	23.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[1.9]	[0.5]	[2.3]	[5.6]	[9.8]	[18.4]	[24.0]	[37.3]	[63.0]	[80.6]	[146.1]	[216.6]	[431.2]	[474.7]	[22.5]	(22.1; 25.5)
Wallonia	0	0	0	0	0	0	1	1	5	2	17	23	49	50	79	65	74	70	27	8	471	32.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.9]	[4.3]	[1.6]	[13.7]	[18.4]	[42.7]	[51.1]	[91.4]	[133.9]	[205.9]	[334.3]	[356.3]	[569.0]	[26.4]	(29.1; 35.1)
Females																						
<b>Belgium</b>	0	1	0	0	0	1	7	6	7	16	18	46	62	91	115	120	191	224	133	58	1,096	15.8
	[0.0]	[0.3]	[0.0]	[0.0]	[0.0]	[0.3]	[1.9]	[1.6]	[1.9]	[4.3]	[4.6]	[11.5]	[16.7]	[27.9]	[38.8]	[56.3]	[103.2]	[165.7]	[200.7]	[301.6]	[18.8]	(14.8; 16.7)
Brussels	0	1	0	0	0	0	1	0	0	1	2	5	5	2	10	7	24	19	5	2	84	15.4
	[0.0]	[2.6]	[0.0]	[0.0]	[0.0]	[0.0]	[1.9]	[0.0]	[0.0]	[2.5]	[5.4]	[14.9]	[16.8]	[8.2]	[46.4]	[43.1]	[175.2]	[187.0]	[87.1]	[102.2]	[13.5]	(12.0; 18.7)

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Flanders	0	0	0	0	0	1	4	2	3	9	7	22	30	45	64	74	93	143	83	39	619	14.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.9]	[1.0]	[1.4]	[4.3]	[3.1]	[9.2]	[13.6]	[23.3]	[36.8]	[55.5]	[80.1]	[168.2]	[207.0]	[347.3]	[18.4]	(13.3; 15.6)
Wallonia	0	0	0	0	0	0	2	4	4	6	9	19	27	44	41	39	74	62	45	17	393	18.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.7]	[3.5]	[3.5]	[4.9]	[7.3]	[14.9]	[22.3]	[40.5]	[40.7]	[61.2]	[134.1]	[154.8]	[220.4]	[281.4]	[21.1]	(16.6; 20.3)



## 7. CANCER MORTALITY TRENDS



### 7.1. Colorectal cancer mortality trends: by region

7.1.1. Colorectal cancer mortality\* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period	
Belgium	<b>N</b>	1,459	1,535	1,501	1,540	1,577	1,546	1,580	1,546	1,572	1,494	1,442	1,530	1,482	1,514	1,348	1,348	1,321	1,323			
	<b>CR</b>	28.7	30.0	29.2	29.7	30.2	29.3	29.7	28.8	29.0	27.4	26.3	27.8	26.8	27.2	24.1	24.0	23.3	23.3			
	<b>ESR2013</b>	41.6	44.5	41.9	40.5	41.3	39.7	39.4	37.7	37.6	35.9	33.1	34.3	32.7	32.3	28.3	28.0	26.9	26.7	-2.9 (-3.2; -2.6)	2004-2021	
																				-1.8 (-2.4; -1.1)	2004-2012	
																					-3.9 (-4.5; -3.4)	2013-2021
Brussels	<b>N</b>	114	129	118	130	107	138	123	127	120	109	106	109	116	132	114	109	103	110			
	<b>CR</b>	23.7	26.7	24.1	26.2	21.2	26.7	23.3	23.4	21.7	19.4	18.7	19.0	20.0	22.7	19.4	18.4	17.2	18.4			
	<b>ESR2013</b>	39.3	43.6	39.3	42.0	32.7	43.2	39.4	38.4	37.2	33.3	31.6	33.2	32.6	38.1	32.3	32.0	27.5	31.7			
																					-1.7 (-2.3; -1.1)	2004-2021
Flanders	<b>N</b>	928	948	957	928	915	973	983	958	984	908	858	968	884	881	798	780	760	742			
	<b>CR</b>	31.3	31.8	31.9	30.8	30.1	31.8	31.9	30.8	31.4	28.8	27.1	30.4	27.6	27.3	24.6	23.9	23.2	22.5			
	<b>ESR2013</b>	43.6	44.8	43.7	40.0	39.9	40.3	39.7	38.0	38.1	35.2	31.9	34.7	31.2	29.9	26.8	25.6	24.5	23.8			
																					-1.9 (-2.7; -1.1)	2004-2021
																					-2.0 (-2.8; -1.3)	2004-2012
																					-5.1 (-5.7; -4.4)	2013-2021
Wallonia	<b>N</b>	417	458	426	482	555	435	474	461	468	477	478	453	482	501	436	459	458	471			
	<b>CR</b>	25.4	27.8	25.7	28.9	33.1	25.8	27.9	26.9	27.1	27.5	27.4	25.9	27.4	28.4	24.6	25.8	25.7	26.4			

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
<b>ESR2013</b>	37.8	44.1	39.0	40.5	46.7	37.3	38.6	37.3	36.5	38.5	36.1	33.8	35.6	36.0	30.5	32.0	31.6	32.1	-3.7 (-4.0; -3.3)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Colorectal cancer mortality\* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period	
Belgium	<b>N</b>	1,394	1,398	1,417	1,416	1,397	1,494	1,348	1,385	1,401	1,372	1,315	1,278	1,272	1,313	1,244	1,278	1,199	1,096			
	<b>CR</b>	26.3	26.2	26.4	26.2	25.7	27.2	24.4	24.8	24.9	24.3	23.2	22.4	22.2	22.8	21.5	22.0	20.6	18.8			
	<b>ESR2013</b>	26.2	26.0	25.6	25.2	24.4	25.9	22.5	22.9	22.8	22.0	20.8	19.9	19.6	19.9	18.6	18.8	17.2	15.8	-2.7 (-3.0; -2.4)	2004-2021	
																				-1.9 (-2.7; -1.2)	2004-2012	
																					-3.4 (-4.1; -2.7)	2013-2021
Brussels	<b>N</b>	139	134	151	117	130	138	124	123	121	113	118	123	90	113	116	116	98	84			
	<b>CR</b>	26.8	25.6	28.5	21.9	24.0	25.0	22.0	21.3	20.6	19.1	19.8	20.4	14.8	18.5	19.0	18.8	15.8	13.5			
	<b>ESR2013</b>	25.6	25.2	27.9	21.5	24.7	26.2	22.1	22.1	21.4	20.1	20.3	22.4	16.4	20.0	21.5	21.2	17.5	15.4	-1.6 (-2.0; -1.2)	2004-2021	
Flanders	<b>N</b>	792	810	823	820	807	855	789	796	816	775	748	702	738	736	688	709	644	619			
	<b>CR</b>	26.0	26.4	26.7	26.4	25.9	27.2	24.9	24.9	25.4	24.0	23.1	21.5	22.5	22.3	20.8	21.3	19.2	18.4			
	<b>ESR2013</b>	26.1	26.5	25.9	25.4	24.4	25.4	22.6	22.6	22.7	21.2	20.1	18.5	19.0	18.6	17.1	17.3	15.2	14.5	-2.4 (-3.3; -1.5)	2004-2021	
																				-2.1 (-2.9; -1.2)	2004-2011	
																					-4.2 (-4.8; -3.7)	2012-2021
Wallonia	<b>N</b>	463	454	443	479	460	501	435	466	464	484	449	453	444	464	440	453	457	393			
	<b>CR</b>	26.6	26.0	25.2	27.1	25.9	28.0	24.2	25.7	25.5	26.5	24.5	24.6	24.1	25.1	23.7	24.4	24.5	21.1			
	<b>ESR2013</b>	26.5	25.5	24.6	25.9	24.5	26.7	22.4	23.6	23.6	23.9	22.1	21.8	21.7	22.2	20.8	21.3	21.1	18.5	-3.3 (-3.7; -3.0)	2004-2021	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

\*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Recommended reference: Cancer Fact Sheets 2022, Belgian Cancer Registry (BCR), 2024